TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20187094
Drug: Intravenous chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemoradiation
Study: 14529100
Drug: Albuterol 180
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 180 microg
Study: 3919531
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus glibenclamide, 5 mg twice daily
Study: 31174713
Drug: Double-blind injectable
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind injectable opioid agonist treatment (iOAT)
Study: 26884557
Drug: CGA arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGA arm (treatment allocation based on Comprehensive Geriatric Assessment)
Study: 26884557
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm (chemotherapy allocation based on performance status and age)
Study: 19625343
Drug: Irinotecan (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (70 mg/m²) and Docetaxel (25 mg/m²) administered on days 1 and 8 of each 3-week cycle
Study: 16353468
Drug: Centric occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centric occlusion stabilization oral appliance
Study: 9809926
Drug: Arotinolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol (10 mg twice a day)
Study: 8561267
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (total dose = 550 mg or 9.6 mg/kg)
Study: 8561267
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (total dose = 8.8 mg/kg)
Study: 2692838
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol (LA.P), 160 mg once-daily
Study: 322152
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (2 and 10 mg)
Study: 31145281
Drug: 4 SMS
Normalized name: Somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 SMS per week offering advice, motivation, and information about medication adherence, physical activity, dietary measures, and smoking cessation (if appropriate)
Study: 27008585
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise (combination of aerobic and resistance protocols, 60 minutes)
Study: 21288211
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg pre-incision
Study: 21288211
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg pre-incision
Study: 21288211
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg post-incision
Study: 21288211
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg post-incision
Study: 16189334
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg pre-incision
Study: 16189334
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg post-incision
Study: 16424410
Drug: All formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formoterol treatment regimens
Study: 12819323
Drug: Recommended anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended anti-hypertensive therapy
Study: 8247239
Drug: Dexamethasone in
Normalized name: Dexamethasone Intensol
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone in high but rapidly decreasing doses
Study: 2935349
Drug: Metoprolol (1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (1.25, 1.25, 2.5, and 5.0 mg)
Study: 31702643
Drug: HT080 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT080 (500 mg) twice a day for 12 weeks
Study: 31702643
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 12 weeks
Study: 23192600
Drug: Daily Disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Disturbances factor of PSQI
Study: 21311402
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (open discectomy)
Study: 17164728
Drug: Sirolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (10 mg loading dose followed by 3 mg/m²/day, target levels 10-15 ng/mL for 6 months, then 5-10 ng/mL thereafter)
Study: 17164728
Drug: Cyclosporine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (4 to 8 mg/kg/day, target levels 150-300 ng/mL for 6 months, then 100-200 ng/mL thereafter)
Study: 9407377
Drug: Saquinavir (SQV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir (SQV, Invirase) treatment
Study: 8428855
Drug: Theophylline 300
Normalized name: theophylline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 300 mg twice a day (R1)
Study: 8428855
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg tid (R2)
Study: 8428855
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (200/4mg, R3)
Study: 8428855
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (100/2mg, R4)
Study: 8428855
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium lactate 300 mg) tid (R5)
Study: 27098449
Drug: Dietary feedback
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary feedback and weekly text messages
Study: 22241281
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg risperidone
Study: 16390852
Drug: Impaired renal
Normalized name: nut.tx.impaired renal fxn,soy ORAL BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired renal function (estimated glomerular filtration rate <60 ml/min/1.73 m²) in men and women aged 65 years or older
Study: 16390852
Drug: Cardiovascular drug
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug prescriptions (angiotensin-converting enzyme inhibitors and beta-blockers)
Study: 10939683
Drug: Scopolamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (1.5 mg, transdermal patch)
Study: 10939683
Drug: Cyclizine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine (50 mg tablet)
Study: 19350339
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate treatment
Study: 22078189
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg twice daily on day 1 plus placebo 1 daily for 4 days
Study: 22078189
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg twice daily on day 1 plus ethinyl estradiol (EE) 20 mcg daily for days 2-5
Study: 11477920
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy
Study: 15074086
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) alone
Study: 8576842
Drug: Teicoplanin loading
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin loading doses of 6 to 30 mg/kg, followed by once-a-day treatment of approximately the same doses over several weeks.
Study: 30703258
Drug: BMS-986231 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986231 0.1, 0.33, 1, 3, 5, 10, and 15 μg/kg/min infused over 24 hours
Study: 30703258
Drug: BMS-986231 10
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986231 10 μg/kg/min infused over 48 hours
Study: 26895920
Drug: Protective lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective lung ventilation (low tidal volume of 6 ml/kg with PEEP of 5 cmH2O)
Study: 26895920
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation with alveolar recruitment maneuver (tidal volume of 10 ml/kg with inspiratory pressure of 40 cmH2O for 30s)
Study: 15957991
Drug: Temporising treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporising treatment of severe early onset pre-eclampsia
Study: 1767898
Drug: Continuous lumbar
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lumbar epidural infusion of morphine
Study: 1767898
Drug: Continuous lumbar
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lumbar epidural infusion of fentanyl
Study: 1767898
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of loratadine
Study: 7332913
Drug: Elixophyllin SR
Normalized name: THEOPHYLLINE 125MG CAP,SA (ELIXOPHYLLIN SR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixophyllin SR capsules
Study: 25059332
Drug: Oral moisturising
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral moisturising gel containing egg yolk antibodies against Candida albicans (anti‐CA IgY)
Study: 25059332
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral moisturising gel without anti‐CA IgY
Study: 22440906
Drug: Biocompatible solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible solution
Study: 19514864
Drug: losartan 25mg/chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 25mg/chlorthalidone 6.25 mg
Study: 19514864
Drug: losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 25 mg/hydrochlorothiazide 12.5 mg
Study: 19514864
Drug: losartan 25mg/chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 25mg/chlorthalidone 12.5 mg
Study: 11985943
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (50 ml curd containing Lactobacillus acidophilus)
Study: 11985943
Drug: Isocaloric supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric supplement (control group)
Study: 7636683
Drug: Packaged rice-based
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packaged rice-based oral rehydration solution (R-ORS)
Study: 7636683
Drug: Standard glucose-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose-electrolyte oral rehydration solution (G-ORS)
Study: 367712
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 to 800 mg daily)
Study: 367712
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 to 1000 mg daily)
Study: 31517745
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin administered 12 hours before the operation
Study: 31517745
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin administered 1 hour before the operation
Study: 21157403
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sotrastaurin twice daily with standard-exposure tacrolimus (treatment B)
Study: 21157403
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sotrastaurin twice daily with reduced-exposure tacrolimus (treatment C)
Study: 21157403
Drug: mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mycophenolic acid (MPA) with standard-exposure tacrolimus (treatment A)
Study: 17556790
Drug: Isotretinoin (Acutaneï)
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin (Acutaneï) therapy
Study: 17556790
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or topical acne therapy (control group)
Study: 37060
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.1 and 0.25 mg in 1 ml solution)
Study: 37060
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (protective application before antigen inhalation)
Study: 17373090
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day + aggressive debridement
Study: 17373090
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day alone
Study: 15111485
Drug: Liraglutide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (6 micro g/kg) administered subcutaneously once daily
Study: 11813932
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% twice daily (treatment-naive)
Study: 11813932
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily (treatment-naive)
Study: 11813932
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% twice daily (previously treated)
Study: 11813932
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily (previously treated)
Study: 11502237
Drug: Yoghurt-based drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt-based drink enriched with 1 g plant sterol extracted from soyabean/d
Study: 11502237
Drug: Yoghurt-based drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt-based drink enriched with 2 g plant sterols/d
Study: 9041099
Drug: Ursodiol (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol (13 to 15 mg per kilogram of body weight per day in divided doses)
Study: 1978115
Drug: L1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L1 (50 mg/kg daily by mouth)
Study: 1978115
Drug: Desferrioxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (50 mg/kg daily as a 12 h subcutaneous infusion)
Study: 29938533
Drug: Ranolazine (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (6-week add-on therapy)
Study: 29938533
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without additional study medication (Control)
Study: 28658582
Drug: Acute nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute nitrate supplementation (10 mg·kg‐1 body mass of sodium nitrate)
Study: 23666445
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ascorbic acid (7.5 g)
Study: 17374416
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg daily for 30 days
Study: 11782329
Drug: IT fentanyl
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT fentanyl 25 microg plus plain bupivacaine 1.25 mg (Group f+pb)
Study: 11782329
Drug: IT fentanyl
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT fentanyl 25 microg plus heavy bupivacaine 1.25 mg (Group f+hb)
Study: 9824781
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenously
Study: 8799530
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg orally
Study: 9824781
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenously or 40 mg orally every 12 hours
Study: 8861410
Drug: Behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural treatment including applied relaxation, video self‐modelling, exposure, information, and teaching of hearing tactics
Study: 7086742
Drug: Behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural treatment
Study: 2667324
Drug: epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i.v. once every 3 weeks
Study: 2667324
Drug: 5-fluorouracil 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil 500 mg/m2 (450 mg/m2 if prior radiotherapy) i.v. once daily for 5 consecutive days every 4 weeks
Study: 1106936
Drug: 220 mg
Normalized name: urea 220 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg of naproxen
Study: 1106936
Drug: 330 mg
Normalized name: urea 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mg of naproxen
Study: 30559067
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (systemically administered opioids)
Study: 23647445
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg once daily for 6 months
Study: 21596735
Drug: L-arginine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine plus antioxidant vitamins
Study: 11427637
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) given as a bolus of 1 mg/kg bodyweight followed by a constant infusion of 0.1 mg/kg bodyweight for 210 min during dialysis
Study: 9531074
Drug: Meropenem (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (0.5 g 8-hourly)
Study: 9531074
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g 8-hourly)
Study: 8028055
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (TPN)
Study: 8028055
Drug: Parenteral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral plus enteral nutrition (PN/EN)
Study: 30911756
Drug: 2× daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2× daily feeding (half ration at 0730 and 1530 h)
Study: 30911756
Drug: 3× daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3× daily feeding (a third portion at 0730, 1130, and 1530 h)
Study: 30911756
Drug: 2× daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2× daily feeding
Study: 30911756
Drug: 3× daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3× daily feeding
Study: 24178238
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (2 mg/24 h) applied for 24 h
Study: 20031846
Drug: Uncertainty reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertainty reduction intervention (provided in 5 clinics) including access to a specially designed study form with blood pressure graphs, assessment checkboxes, and a menu of services (24-hour ambulatory blood pressure monitoring, electronic bottle cap assessment of medication adherence, lifestyle assessment and counseling).
Study: 20430601
Drug: Ciclesonide 80
Normalized name: CICLESONIDE 80MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 80 microg once daily
Study: 14977388
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 microg daily
Study: 14977388
Drug: Ciclesonide 80
Normalized name: CICLESONIDE 80MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 80 or 320 microg daily
Study: 9741504
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral atenolol
Study: 2525897
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol
Study: 30552406
Drug: Telmisartan +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan + Low-dose rosuvastatin
Study: 30552406
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Low-dose rosuvastatin
Study: 23801303
Drug: Cediranib 45
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 45 mg/day plus fulvestrant
Study: 19038708
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PC and BP
Study: 15923042
Drug: Fluoxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine monotherapy 10-30 mg daily
Study: 15923042
Drug: Olanzapine monotherapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine monotherapy 5-20 mg daily
Study: 15923042
Drug: Combined fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fluoxetine plus olanzapine therapy 10-40 mg plus 5-15 mg daily
Study: 8794412
Drug: Chemo-immunotherapy (IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy (IL-2 and LAK cells after two courses of anticancer chemotherapy)
Study: 8794412
Drug: Chemotherapy (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (same anticancer chemotherapy as group A)
Study: 3522507
Drug: Piracetam (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (3.3 g/day in two divided doses for 12 weeks)
Study: 29341461
Drug: Exenatide infusion
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide infusion (Study-A)
Study: 29341461
Drug: Exenatide infusion
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide infusion (Study-B)
Study: 22622291
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus Ketamine (1.5 mg/kg + 0.8 mg/kg)